


# ProbioMax® Plus DF

Comprehensive Support for Gut Ecology\*



Available in 30 stick packs

## Discussion

Supplementation with probiotics has many mechanisms of action that benefit health, including but not limited to: (1) supporting metabolic activity, such as the production of short-chain fatty acids and vitamins, nutrient absorption, and digestion of lactose; (2) adhering to intestinal epithelial cells to help maintain a healthy balance of organisms in the intestinal tract; (3) helping to establish populations of good bacteria after disruption in balance; (4) supporting immune function; (5) promoting intestinal epithelial cell survival; (6) supporting healthy bowel function; and (7) degrading oxalates.\*<sup>[1-8]</sup>

**HOWARU® (*Bifidobacterium lactis* HN019)** Discovered in 1899, *B. lactis* plays a key role in the human microflora throughout a person's life. Researchers have identified strain HN019 as having excellent probiotic potential based upon its ability to survive the transit through the human gastrointestinal tract, adhere to epithelial cells, and proliferate.<sup>[6]</sup> *B. lactis* HN019 has been extensively studied, and its safety and effectiveness is well-accepted.<sup>[7,8]</sup> To assess the impact of *B. lactis* HN019 supplementation on whole-gut transit time in adults, 100 subjects were given daily doses for 14 days of 17.2 billion colony-forming units (CFU), 1.8 billion CFU, or placebo. Decreases in mean whole-gut transit time over the 14-day study period were statistically significant in the high-dose group and the low-dose group, but not in the placebo group.<sup>[8]</sup> This level of dosing also supported other parameters of healthy GI function, as were self-reported by patient survey.<sup>[8]</sup> In another study of preschool-age children, supplementing milk for one year with 1.9 x 10 CFU per day *B. lactis* HN019 and 2.4 g/day of prebiotic oligosaccharides supported both healthy iron status and weight gain.<sup>[9]</sup> In a randomized, double-blind, placebo-controlled human dietary intervention study in elderly subjects (>60 yrs.), supplementary *B. lactis* HN019 resulted in statistically significant increases in the beneficial organisms bifidobacteria and lactobacilli.\*<sup>[10]</sup>

***Lactobacillus acidophilus* (*Lactobacillus acidophilus* La-14)** This common inhabitant of the human mouth, intestinal tract, and vagina is also found in some traditional fermented milks (e.g., kefir) and is widely used in probiotic foods and supplements. It has a history of

## Clinical Applications

- » Maintains Healthy Intestinal Microecology, Neutralizes Certain Bacterial Toxins\*
- » Supports Balance of Healthy Intestinal Flora\*
- » Supports the Natural Immune Response\*
- » Supports Bowel Regularity\*
- » Enhances Integrity of Mucosa and Enzymatic Activity of the Intestinal Cells\*
- » Positively Affects the Production of Cytokines\*

*ProbioMax® Plus DF* is an ideal combination of ingredients for individuals seeking a well-rounded supplement to address intestinal ecology, cellular health, and immunity. It features well-researched probiotic strains; *Saccharomyces boulardii*, a non-pathogenic yeast; and arabinogalactan, a prebiotic. By combining these ingredients, the individual benefits of each component can be complemented by the mechanisms of the others.\*

safe human consumption. The *L. acidophilus* La-14 strain is of human origin and has been identified as a type A1 *L. acidophilus*. *L. acidophilus* shows excellent adhesion to human epithelial cell-lines.\*<sup>[11,12]</sup>

***Lactobacillus plantarum* (*Lactobacillus plantarum* Lp-115)** This bacteria was isolated from plant material and is abundantly present in lactic acid-fermented foods, such as olives and sauerkraut. In vitro studies have shown that *L. plantarum* strain Lp-115 has excellent adhesion to epithelial cell lines.<sup>[13]</sup> In addition, *L. plantarum* is resistant to low pH conditions and survives the presence of bile at duodenal concentrations.\*<sup>[13,14]</sup>

***Bifidobacterium longum* (*Bifidobacterium longum* B1-05)** The *B. longum* B1-05 strain is well-accepted as safe for human consumption. *B. longum* is resistant to low pH and bile salts and is well-suited to the intestinal environment.\*<sup>[14]</sup>

***Saccharomyces boulardii*** is a natural, non-pathogenic yeast that has been shown to maintain and restore the healthy ecology of the small and large intestines. In a 2010 systematic review and meta-analysis of 31 randomized placebo-controlled treatment arms in 27 trials (encompassing 5,029 adult study patients), *S. boulardii* was found to be significantly efficacious and safe in 84% of those treatments arms. Extensively researched and published in European and American peer-reviewed journals, *S. boulardii* has demonstrated multiple mechanisms of action. These can be found by referring to DRS-109, which details XYMOGEN's Saccharomycin DF™. The *S. boulardii* used in this formula is processed by low temperature vacuum drying for improved stability.\*<sup>[15-17]</sup>

XYMOGEN has also included the prebiotic **Arabinogalactan** in ProbioMax Plus DF. Present in many plants, arabinogalactan is a non-digestible, soluble dietary fiber that contains the monosaccharides galactose and arabinose. The generally recognized as safe (GRAS) source of arabinogalactan in this formula is the larch tree. In addition

*Continued on next page*

EXCLUSIVE • PATENTED

\*These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.

XYMOGEN® Exclusive Professional Formulas  
800-647-6100 | www.xymogen.com

**ProbioMax® Plus DF Supplement Facts**

Serving Size: 1 Stick Pack (about 2.3 g)

	Amount Per Serving	%Daily Value
Calories	5	
Total Carbohydrate	1 g	0% <sup>‡</sup>
Dietary Fiber	1 g	4% <sup>‡</sup>
Arabinogalactan (from <i>Larix laricina</i> (heartwood)	1.5 g	**
Saccharomyces boulardii	500 mg (10 Billion CFU <sup>†</sup> )	**
Proprietary Blend <i>Lactobacillus acidophilus</i> La-14 <i>Bifidobacterium longum</i> Bl-05 <i>Lactobacillus plantarum</i> Lp-115	174 mg (15 Billion CFU <sup>†</sup> )	**
HOWARU® Bifido ( <i>Bifidobacterium lactis</i> HN019)	50 mg (15 Billion CFU <sup>†</sup> )	**

<sup>‡</sup>Percent Daily Values are based on a 2,000 calorie diet.  
<sup>†</sup>Colony-Forming Unit  
 \*\*Daily Value not established.

**Other Ingredients:** Silica.  
 †Colony-Forming Unit

**HOWARU® is a registered trademark of Danisco A/S and used under license.**

**DIRECTIONS:** Dissolve the contents of one stick pack in 1–2 oz pure water and consume one to three times daily, or take as directed by your healthcare practitioner.

Consult your healthcare practitioner prior to use, especially if you have severe immune suppression. Individuals taking antifungal or other medication should discuss potential interactions with their healthcare practitioner. Do not use if tamper seal is damaged.

**DOES NOT CONTAIN:** Wheat, gluten, soy, animal or dairy products, fish, shellfish, peanuts, tree nuts, egg, ingredients derived from genetically modified organisms (GMOs), artificial colors, artificial sweeteners, or artificial preservatives.

**STORAGE:** Keep tightly closed in a cool, dry place out of reach of children.

**HOWARU®**

to its involvement in cellular communication and possession of immune-supporting properties, arabinogalactan minimizes ammonia synthesis and absorption, enhances production of short-chain fatty acids, and favorably alters gut microflora.\*

## References

- Vanderpool C, Yan F, Polk DB. Mechanisms of probiotic action: Implications for therapeutic applications in inflammatory bowel diseases. *Inflamm Bowel Dis*. 2008 Nov;14(11):1585-96. [PMID: 18623173]
- Abrott VR, Reid SJ. Oxalate-degrading bacteria of the human gut as probiotics in the management of kidney stone disease. *Adv Appl Microbiol*. 2010;72:63-87. [PMID: 20602988]
- Masood MI, Qadir MI, Shirazi JH, et al. Beneficial effects of lactic acid bacteria on human beings. *Crit Rev Microbiol*. 2011 Feb;37(1):91-98. [PMID: 21162695]
- Turroni S, Vitali B, Bendazzoli C, et al. Oxalate consumption by lactobacilli: evaluation of oxalyl-CoA decarboxylase and formyl-CoA transferase activity in *Lactobacillus acidophilus*. *J Appl Microbiol*. 2007 Nov;103(5):1600-09. [PMID: 17953571]
- Shu Q, Lin H, Rutherford KJ, et al. Dietary *Bifidobacterium lactis* (HN019) enhances resistance to oral *Salmonella typhimurium* infection in mice. *Microbiol Immunol*. 2000;44(4):213-22. [PMID: 10832963]
- Gopal P, et al. Effects of the consumption of *Bifidobacterium lactis* HN019 (DR10TM) and galacto-oligosaccharides on the microflora of the gastrointestinal tract in human subjects. *Nutr Res*. 2003;23(10):1313-28. [http://www.nrjournal.com/article/S0271-5317\(03\)00134-9/abstract](http://www.nrjournal.com/article/S0271-5317(03)00134-9/abstract). Accessed June 24, 2011.
- Danisco. Clinical study bibliography and abstracts. <http://www.danisco.com/product-range/probiotics/howarur-premium-probiotics/howaru-r-bifido-probiotics/howaru-bifido-clinical-studies/>. Accessed April 14, 2014.
- Waller PA, Gopal PK, Leyer GJ, et al. Dose-response effect of *Bifidobacterium lactis* HN019 on whole gut transit time and functional gastrointestinal symptoms in adults. *Scand J Gastroenterol*. 2011 Sep;46(9):1057-64. [PMID: 21663486]
- Sazawal S, Dhingra U, Hiremath G, et al. Effects of *Bifidobacterium lactis* HN019 and prebiotic oligosaccharide added to milk on iron status, anemia, and growth among children 1 to 4 years old. *J Pediatr Gastroenterol Nutr*. 2010 Sep;51(3):341-46. [PMID: 20601905]
- Ahmed M, Prasad J, Gill H, et al. Impact of consumption of different levels of *Bifidobacterium lactis* HN019 on the intestinal microflora of elderly human subjects. *J Nutr Health Aging*. 2007 Jan-Feb;11(1):26-31. [PMID: 17315077]
- Greene JD, Klaenhammer TR. Factors involved in adherence of lactobacilli to human Caco-2 cells. *Appl Environ Microbiol*. 1994 Dec;60(12):4487-94. [PMID: 7811085]
- Kleeman EG, Klaenhammer TR. Adherence of *Lactobacillus* species to human fetal intestinal cells. *J Dairy Sci*. 1982 Nov;65(11):2063-69. [PMID: 7153393]
- Collado MC, Meriluoto J, Salminen S. Role of commercial probiotic strains against human pathogen adhesion to intestinal mucus. *Lett Appl Microbiol*. 2007 Oct;45(4):454-60. [PMID: 17897389]
- Ding WK, Shah NP. Acid, bile, and heat tolerance of free and microencapsulated probiotic bacteria. *J Food Sci*. 2007 Nov;72(9):M446-50. [PMID: 18034741]
- McFarland LV. Systematic review and meta-analysis of *Saccharomyces boulardii* in adult patients. *World J Gastroenterol*. 2010 May 14;16(18):2202-22. [PMID: 20458757]
- Vandenplas Y, Brunser O, Szajewska H, et al. *Saccharomyces boulardii* in childhood. *Eur J Pediatr*. 2009 Mar;168(3):253-65. [PMID: 19096876]
- Buts JP, De Keyser N. Effects of *Saccharomyces boulardii* on intestinal mucosa. *Dig Dis Sci*. 2006 Aug;51(8):1485-92. [PMID: 16838119]

Additional references available upon request

**EXCLUSIVE • PATENTED**

All XYMOGEN® Formulas Meet or Exceed cGMP Quality Standards.

\*These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.